

DATE: January 7, 2006

NAME OF PETITIONER: U.S. Canola Association

POST OFFICE ADDRESS: 600 Pennsylvania Ave., SE, Suite 320
Washington, DC 20003

SUBJECT OF PETITION: Petition for the Authorization of a Qualified Health
Claim for Unsaturated Fatty Acids from Canola Oil
and Reduced Risk of Coronary Heart Disease

SUBMITTED TO: Office of Nutritional Products, Labeling and
Dietary Supplements (HFS-800)
Center for Food Safety and Applied Nutrition
Food and Drug Administration
Harvey W. Wiley Federal Building
5100 Paint Branch Parkway
College Park, MD 20740

TABLE OF CONTENTS

I.	INTRODUCTION	
A.	Background	1
B.	Regulatory precedent	2
1.	T-C and LDL-C appropriate biomarkers for CHD	2
2.	UFAs are an appropriate substance for health claims	3
3.	FDA invited interested parties to petition for a health claim for vegetable oils high in UFAs	4
4.	FDA authorized a health claim for phytosterols and reduced risk of CHD	4
C.	Prioritization	5
II.	PRELIMINARY REQUIREMENTS	
A.	UFAs from canola oil are associated with a disease affecting the general U.S. population	7
B.	UFAs contribute nutritive value to the diet and functionality to food products	8
C.	UFAs are safe and lawful	8
III.	SUMMARY OF SCIENTIFIC DATA	
A.	Credible scientific evidence exists to support the claim	10
B.	Scientific evidence demonstrates the public health benefits of UFAs from canola oil	12
1.	UFAs lower serum lipids when they replace dietary SFAs and <i>trans</i> fatty acids	12
2.	PUFAs and MUFAs have beneficial effects on lipids independent of their ability to replace SFAs	13
3.	PUFAs reduce the incidence of CHD	16
4.	Alpha-linolenic acid may be cardioprotective	18
5.	Other constituents in canola oil may be cardioprotective	22
C.	Scientific publications on UFAs from canola oil and CHD	24
1.	Observational studies	25
2.	Intervention studies	26
3.	Summary of scientific publications on UFAs from canola oil and CHD	53
D.	Recommendations from governmental and professional organizations	56
1.	Dietary Guidelines for Americans	56
2.	Healthy People 2019	57
3.	National Cholesterol Education Program Adult Treatment Panel III	57
4.	American Heart Association	57
5.	Other organizations	58
E.	Summary and conclusions	59
F.	Other scientific summary considerations	61
1.	Is there an optimum level of UFAs to be consumed beyond which no benefit would be expected?	61
2.	Is there any level at which an adverse effect from UFAs or from foods containing UFAs (e.g., canola oil) occurs for any segment of the population?	62
3.	Are there certain populations that must receive special consideration?	68
4.	What other nutritional or health factors (both positive and negative) are important to consider when consuming UFAs?	68
G.	Prevalence of CHD in the U.S. population and the relevance of the claim in the total diet	71
H.	UFAs are a substance under 21 CFR § 101.14 (a)(2)	72
IV.	MINIMUM EFFECTIVE DOSE	74

V.	NATURE OF THE FOOD ELIGIBLE TO BEAR THE CLAIM	77
A.	Minimum amount of canola oil per RACC	77
B.	Total fat content	79
C.	Saturated and <i>trans</i> fat content	81
D.	Cholesterol content	82
E.	Exemptions	82
1.	Total fat disqualifier level	82
2.	10% DV minimum nutrient content requirement	85
VI.	LABELING REQUIREMENTS	87
VII.	ANALYTICAL METHODS (COMPLIANCE WITH THE CLAIM)	87
VIII.	PROPOSED MODEL HEALTH CLAIMS	88
A.	Consumer research: composition of the panel and methodology	88
B.	Consumer research: results	91
C.	Recommended health claim language	93
IX.	ENVIRONMENTAL IMPACT ASSESSMENT	94
X.	CONCLUSION AND CERTIFICATION	95
XI.	BIBLIOGRAPHY	97
	Appendix A – Summaries of intervention studies	
	Appendix B – Dietary modeling study	
	Appendix C – Consumer research panel composition	
	Appendix D – Consumer research methodology and results	
	Appendix E – Literature search	
	Appendix F – References	